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Abstract
Background: This 1-year prospective cohort study aimed to compare the changes in clinical symptoms and
functional disability between patients with coexisting patellofemoral (PF) and tibiofemoral (TF) osteoarthritis (OA)
and those with isolated TFOA.
Methods: Seventy-two patients with medial knee OA were enrolled. Knee pain and functional disability were assessed
at baseline and at 1-year follow-up using the Japanese Knee Osteoarthritis Measure (JKOM) and a visual analog scale
(VAS). We performed two-way analysis of covariance for the clinical outcome variables to examine, time (baseline and
follow-up), group (coexisting PFOA and isolated TFOA), and time-group interaction effects. Furthermore, we conducted
post-hoc exploratory analysis to address the possibility that dividing patients according to location of PFOA (i.e., isolated
lateral, isolated medial, and mixed [bilateral]) may identify a distinct subgroup with different changes in clinical outcomes
at 1-year follow-up.
Results: We detected group effects only in scores of the JKOM pain subscale (P = 0.012) and VAS (P = 0.033), adjusted
for age, sex, and body mass index. Patients with coexisting PFOA have stable moderate level knee pain and functional
disability throughout the year which is significantly worse than that in those with isolated TFOA. Post-hoc subgroup
analysis demonstrated that change of knee pain likely varied with location of PFOA. Patients with isolated lateral PFOA
had mild/moderate level knee pain, and their VAS scores were likely to improve, whereas those with mixed PFOA
exhibited stable to worsening moderate/severe knee pain.
Conclusions: Although we did not detect differences in changes in clinical symptoms and functional disability between
patients with coexisting PFOA and those with isolated TFOA, our findings indicate that patients with coexisting PFOA
had worse clinical symptoms and functional disability than those with isolated TFOA. The results of the exploratory
analysis suggested that patients with coexisting PFOA might have heterogeneous clinical outcomes, and presence of
mixed PFOA might be an indicator of severe clinical knee OA.
Keywords: Patellofemoral osteoarthritis, Tibiofemoral osteoarthritis, Knee pain, Disability
* Correspondence: aoyama.tomoki.4e@kyoto-u.ac.jp
1Department of Physical Therapy, Human Health Sciences, Graduate School
of Medicine, Kyoto University, Kyoto, Japan
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Iijima et al. BMC Musculoskeletal Disorders  (2017) 18:126 
DOI 10.1186/s12891-017-1486-4
Background
Osteoarthritis (OA) of the knee is a common chronic
and degenerative disease and a major cause of knee pain
and functional disability worldwide [1]. Generally, knee
OA is considered a progressive condition that requires
total joint arthroplasty. However, several studies demon-
strated that, while pain and functional disability generally
worsened over time in patients with knee OA, individual
outcomes were heterogeneous, with worsening in some
patients and improvement in others [2–5]. Thus, there is
a possibility that the pool of patients with knee OA com-
prises a number of subgroups with distinct trajectories of
pain and functional disability, not all of which are progres-
sive. Since identifying these homogenous subgroups would
provide information about clinical prognosis and facilitate
targeted treatment, this topic has become a recent focus
of epidemiologic and clinical studies of knee OA [6, 7].
Although patellofemoral (PF) OA remains an under
recognized type of knee OA, patients with PFOA have
been recently considered a subgroup different from pa-
tients with tibiofemoral (TF) OA [8]. Duncan et al. dem-
onstrated that the prevalence of mixed PFOA and
TFOA in older adults with painful knees is much higher
(40%) than that of TFOA (4%) or PFOA (24%) alone [9].
Since the PF joint contributes more to the symptoms of
knee OA than the TF joint dose [10], presence of PF
joint disease can adversely affect physical activity, par-
ticipation in social life, and quality of life. Indeed, recent
studies demonstrated that patients with coexisting PFOA
and TFOA were more likely to have pain and functional
disability as well as knee-specific impairments such as
quadriceps weakness and restricted range of motion of the
knee joint than those with isolated TFOA did [11–14].
Importantly, increased knee pain and knee-specific im-
pairments are potential risk factors for disease progression
[15], worsening knee pain [16], and activity limitation
[4, 17]. Furthermore, patients with coexisting PFOA are
known to have altered gait biomechanics with more fre-
quent single-leg stance external knee flexion moments
[14], which elevates compressive stresses of the PF [18]
and TF [19] joints and increases the risk of progression
of clinical and radiographic OA.
These studies suggest that patients with coexisting
PFOA may have a natural course of the disease different
from that in patients with isolated TFOA and may exhibit
worsening clinical symptoms and functional disability over
time. However, previous studies that investigated coexisting
PFOA had a cross-sectional design [12, 13]. A longitudinal
cohort study would provide important insights into the
clinical prognosis and treatment options. Additionally, pre-
vious studies that attempted to identify distinct OA sub-
groups did not consider the PF joint [4, 20, 21], although
the trajectory of PF joint disease may differ from that of TF
joint disease [22]. Given that interventions targeting the PF
joint are recommended for patients with PF joint disease
[23–25], such information may help to design an optimal
treatment based on the involvement of different com-
partments. Therefore, this study aimed to compare the
changes in clinical symptoms and functional disability
differences between patients with coexisting PFOA and
isolated TFOA. It was hypothesized that, (i) compared
to patients with isolated TFOA, those with coexisting
PFOA would have worsening clinical symptoms and
functional disability at 1-year follow-up, and (ii) dividing
patients according to location (i.e., isolated lateral, isolated
medial, and mixed) of PFOA could identify a distinct sub-
group with different clinical outcomes at 1-year follow-up.
Methods
Study design and patients
As described in the previous study [12], 143 patients
with medial knee OA were recruited from a community
orthopedics clinic in February, 2014. Patients were iden-
tified through the medical record system, and were con-
secutively recruited from the community orthopedics
clinic in Hiroshima, which is located in a rural, moun-
tainous community. We distributed an advertisement
requesting patients who were visiting the clinics for con-
servative treatment of knee OA. All recruited patients
had a history of pain in one or both knees. The patients
were followed up for 12 months. Inclusion criteria were
(i) age ≥50 years; (ii) radiographic OA of one or both
knees with a Kellgren/Lawrence [K/L] grade [26] ≥ 2,
primarily in the medial tibiofemoral compartment, as
evaluated using anteroposterior weight-bearing radio-
graphs of the TF joint; and (iii) ability to walk inde-
pendently on a flat surface, without walking aids.
Patients with bilateral knee OA were not considered
separately from unilateral cases. The exclusion criteria
were (i) a history of knee surgery, (ii) inflammatory arth-
ritis, (iii) periarticular fracture, (iv) presence of neuro-
logical diseases, or (v) lateral compartment knee OA.
Lateral knee OA was defined as a knee having a K/L
grade ≥2, along with lateral joint space narrowing
(JSN) > medial JSN, and lateral osteophytes > medial
osteophytes, using an Osteoarthritis Research Society
International (OARSI) atlas [27] according to previously
described methods [28, 29]. The Ethical Committee of
Kyoto University approved this study (approval number:
E1923), and written informed consent was obtained from
all participants before enrollment both at baseline and 1-
year follow-up.
Baseline radiographic evaluation of tibiofemoral and
patellofemoral joints
Methods for baseline radiographic evaluation of severity
of OA of the TF and PF joints determination were de-
scribed in detail elsewhere [12]. In brief, the radiographic
Iijima et al. BMC Musculoskeletal Disorders  (2017) 18:126 Page 2 of 11
severity for the TF joint was assessed using the K/L
grading system on the anteroposterior short film view in
the weight-bearing position by an experienced examiner
(TA). Similarly, radiographic severity for the PF joint
was evaluated using the K/L grading system adapted to
the lateral and medial facets of the PF joint by a single
trained examiner (HI). We have previously reported ex-
cellent intra-rater reliability for such radiographic evalu-
ation, with a Kappa coefficient of 0.90 (TF) and 0.80
(PF) [12]. Patellar alignments and trochlear morphology
were evaluated from the skyline view by a single trained
examiner (HI) who evaluated lateral displacement, tilting
angle of the patella, and sulcus angle [12]. Details re-
garding the measurement for the patellar alignments
were described recently [12]. The intrarater reliabilities
were excellent for the lateral displacement (intraclass
correlation coefficient [ICC] = 0.91, 95% confidence
interval [CI] = 0.89–0.93) and tilting angle of the patella
(ICC = 0.96, 95% CI = 0.95–0.97).
Primary outcomes
Severity of self-reported knee pain was evaluated individu-
ally at baseline and 1-year follow-up, using a visual analog
scale (VAS) and the “pain and stiffness” subcategory of the
Japanese Knee Osteoarthritis Measure (JKOM) in person-
specific assessments. The VAS score was interpreted as no
pain (VAS ≤ 10 mm), mild pain (10 mm<VAS ≤ 30 mm),
moderate pain (30 mm<VAS ≤ 60 mm), or severe pain
(VAS > 60 mm) based on previous studies [30, 31]. The
JKOM is a patient-based, self-administered scoring system
that includes four subcategories assessing “pain and
stiffness” (8 questions, 0–32 points), “activities of daily
living” (10 questions, 0–40 points), “participation in social
activities” (5 questions, 0–20 points), and “general health
conditions” (2 questions, 0–8 points), with 100 points set
as the maximum score. For each subscale, a higher score
indicates a worse condition (on a 0–4 Likert scale, 0 indi-
cates no pain or difficulty while 4 represents extreme pain
or difficulty). The concurrent and construct validities of
the JKOM were established by comparing with the
Western Ontario and McMaster Universities Arthritis
Index and the Medical Outcomes Study 36-item Short-
Form Health Survey [32].
Secondary outcomes
Secondary outcomes included the other JKOM subcate-
gories (“activities of daily living,” “participation in social
activities,” and “general health conditions”) evaluated at
both baseline and 1-year follow-up. The JKOM subcate-
gory “activities of daily living” is a self-reported physical
functional assessment reflecting daily activities such as
stair use, bending, standing up from a sitting position,
walking, shopping, taking off socks, and performing light
and heavy household duties.
Measurement of covariates
Data on age, sex, and height were self-reported by the
patients. Weight was measured on a scale, with the par-
ticipants wearing their clothes but not their shoes. Body
mass index (BMI) was calculated by dividing the weight
by the square of height.
Statistical analysis
To minimize bias produced by similarities between the
right and left knees of the same patient [33], only one
knee per patient was analyzed (“index knee”), and a
database was created with one observation per patient.
The index knee was defined as the more painful knee,
currently or in the past. If a patient reported equal pain
in both knees, the index knee was selected randomly. All
continuous data were assessed for following a Gaussian
distribution using the Shapiro–Wilk normality test, and
for homoscedasticity using the F-test. Baseline demo-
graphic characteristics, including radiographic OA severity,
were then compared between patients with coexisting
TFOA and PFOA and isolated TFOA, using the Student’s
t-test for parametric continuous variables, Mann-Whitney
U test for nonparametric continuous variables, or chi-
square/Fisher’s exact tests for dichotomous/categorical
variables. Next, we performed two-way repeated analysis of
covariance (ANCOVA) for clinical outcome variables
(JKOM and VAS scores) to assess the interaction between
time (baseline and 1-year follow-up) and group (coexisting
PFOA and isolated TFOA) adjusted for age (continuous),
sex, and BMI (continuous) and further adjusted for TF
joint K/L grade (continuous). As age, sex, BMI, and TF
joint K/L grade were likely to affect the clinical outcome of
OA [2, 20] and not on the causal pathway, we included
these confounders in the model.
To verify the possibility that dividing patients according
to location of PFOA may identify a distinct subgroup with
different trajectories of clinical outcomes at 1-year follow-
up, we performed explorative subgroup analysis of the re-
lationships between location of PFOA (i.e., isolated lateral,
isolated medial, and mixed [bilateral]) and outcome vari-
ables by using subsamples of patients with coexisting
PFOA. We performed a two-way repeated ANCOVA for
the clinical outcome variables to assess the interaction
between time (baseline and 1-year follow-up) and group
(isolated lateral, isolated medial, and mixed PFOA) ad-
justed for age, sex, BMI, and further adjusted for TF joint
K/L grade, with post-hoc pairwise comparisons. Further-
more, we calculated the percentage of patients having un-
acceptable symptoms representing a clinically relevant
treatment target, defined as a VAS score above 30 mm
[31, 34, 35], and compared these percentages between the
groups using the chi-square test. In the sensitivity ana-
lyses, the type I error rate was not adjusted for multiple
pairwise comparisons as the analysis was exploratory in
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nature. All data analyses were performed with JMP 11
(SAS Institute, Cary, NC, USA) or R (R Foundation for
Statistical Computing, Vienna, Austria). P-values <0.05
were considered to indicate statistical significance.
Results
Our final sample included 72 patients/knees (response
rate: 50.3%) with a K/L grade ≥2 primarily for the medial
compartment. Patients who failed to complete the study
were unable to be contacted or declined to be followed for
non-specific reasons. Baseline characteristics were com-
pared between completers and non-completers (Table 1),
and no significant differences were found between the two
groups in demographic characteristics, OA disease sever-
ity, location of PFOA, patellar alignment, knee pain inten-
sity, and functional disability. Of the 72 patients who
completed the study (age, 56–90 years; 73.6% female), 45
(62.5%) had PFOA with a K/L grade ≥2 of either the late-
ral or the medial PF joint of their index knee. Table 2
shows the baseline characteristics of patients with coexist-
ing PFOA and TFOA (n = 45) and those with isolated
TFOA (without PFOA, n = 27). As mentioned in the re-
cently published paper [12], compared to patients with
isolated TFOA, those with coexisting PFOA tended to be
older and had a significantly higher BMI and a more ad-
vanced disease of the TF joint. Moreover, patients with
coexisting PFOA and TFOA had significantly greater
lateral displacement and lower tilting angle of the pa-
tella (i.e., less lateral rotational position of the patella)
than those with isolated TFOA. Most patients with
coexisting PFOA had either lateral (18 [40.0%]) or
mixed (23 [51.1%]) PFOA, with patients with lateral
PFOA displaying milder disease of the TF and PF joints
compared to those with mixed PFOA (see Additional
file 1: Table S1).
Clinical symptoms and functional disability and their time
dependence
Two-way repeated ANCOVA revealed no significant
time-group interactions at any outcome variables, and
only the group main effect was confirmed for all the out-
come variables adjusted for age, sex, and BMI (Table 3).
Further adjustment for TF joint K/L grade did not sub-
stantially change this result (data not shown). Patients
with coexisting PFOA had worse clinical symptoms
throughout the year than did those with isolated TFOA
as reflected by higher scores in the “pain and stiffness”
subcategory and on the VAS pain score. Thus, moderate
pain (30 mm <VAS ≤ 60 mm) persisted in patients with
coexisting PFOA, although the standard deviations of
the changes in VAS pain score were large (10 [22.2%]
and 18 [40.0%] patients reported improving and worsening
categorized VAS scores, respectively). Additionally, pa-
tients with coexisting PFOA had higher scores in the
“activities of daily living” subcategory (i.e., had more diffi-
culty in daily living) throughout the year.
Explorative subgroup analysis: time dependence of
severity of clinical symptoms and functional disability,
and possible dependence of pain trajectory on location of
patellofemoral osteoarthritis
Explorative subgroup analysis stratified for the patients
with coexisting PFOA showed that pain trajectory
depended on the location of PFOA (Table 4). Two-way
repeated ANCOVA revealed no significant time-group
interactions, and only the group main effect was con-
firmed for the “pain and stiffness” subcategory (adjusted
P-value = 0.012) and VAS score (adjusted P-value =
0.033). Nevertheless, clinical symptoms in patients with
isolated lateral PFOA were likely to decrease during the
1-year follow-up (change in “pain and stiffness”: -1.89, 95%
CI: -4.31, 0.53; change in VAS: -10.8; 95% CI: -21.5, -0.08).
In contrast, clinical symptoms in patients with mixed
PFOA were moderate/severe and stable or worsening
throughout the year (change in “pain and stiffness”: 2.00,
95% CI: -2.71, 6.71; change in VAS: 9.17; 95% CI: -21.0,
39.3). Additionally, a multiple comparison revealed that
“pain and stiffness” and VAS scores in patients with mixed
PFOA were significantly higher than in those with isolated
lateral PFOA when adjusted for age, sex, and BMI (adjusted
P-values for post-hoc pairwise comparison: 0.021 and
0.022, respectively). Moreover, patients with mixed PFOA
had consistently worse scores in the other JKOM sub-
categories and total JKOM score. When TF joint K/L
grade was further adjusted for in the two-way repeated
ANCOVA model, all the main group effects were attenu-
ated (data not shown).
Individual pain trajectories (Fig. 1a) revealed that 7
(38.9%) of the 18 patients with isolated lateral PFOA
were transferred to a lower pain category, whereas none
of the patients with isolated medial PFOA was trans-
ferred to a lower pain category and 3 (75%) of the 4 were
transferred to an upper pain category. Of the 23 patients
with mixed PFOA, 13 (56.5%) and 3 (13.0%) were trans-
ferred to an upper or lower pain category, respectively.
Fig. 1b shows numbers and percentages of patients with
moderate (i.e., 30 mm < VAS ≤ 60 mm) or severe knee
pain (i.e., VAS > 60 mm) corresponding to a state with
unacceptable symptoms and considered a clinically rele-
vant treatment target [31, 34, 35]. The percentage of in-
dividuals having unacceptable symptoms significantly
decreased in patients with isolated PFOA at 1-year
follow-up (from 61.1% to 33.3%; unadjusted P-value =
0.015), but not in those with isolated medial (unadjusted
P-value = 0.486) and mixed (unadjusted P-value = 0.749)
PFOA. Importantly, more than 65% of patients with
mixed PFOA had consistently unacceptable symptoms
throughout the year (change: from 65.1% to 73.9%).
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Discussion
There is growing evidence that coexisting PFOA in pa-
tients with knee OA is common [9], and this mixed
disease is associated with worse clinical symptoms and
low quality of life [11, 12]. Although patients with coex-
isting PFOA are more likely to have potential risk factors
for progression of clinical knee OA because of knee-
specific impairments and altered gait biomechanics
[12–14], little is known about the course of clinical
symptoms and functional disability in such patients.
The present study revealed that clinical symptoms and
functional disability in patients with coexisting PFOA
were persistently bad, but not worsening, throughout the
year (Table 3). Additionally, the exploratory subgroup ana-
lysis demonstrated a possible dependence of pain trajec-
tory on the location of PFOA within the coexisting PFOA
subgroup. Patients with mixed PFOA exhibited stable or
worsening moderate/severe clinical symptoms, whereas
clinical symptoms were likely to improve in those with
isolated lateral PFOA (Table 4 and Fig. 1).
Table 1 Comparison of baseline characteristics between patients with completer and those with non-completera
Variables Completer (n = 72) Non-completer (n = 71) P-value**
Age, years 73.9 ± 8.12 73.5 ± 7.17 0.754
Women, no. (%) 53 (73.6) 55 (77.5) 0.945
Height, meters 1.55 ± 0.08 1.54 ± 0.06 0.862
Weight, kg 58.2 ± 10.3 59.4 ± 10.4 0.471
Body mass index, kg/m2 23.8 ± 4.66 24.9 ± 4.26 0.389
Tibiofemoral joint K/L grade, no. (%) 0.901
Grade 2 48 (66.7) 46 (64.8)
Grade 3 14 (19.4) 16 (22.5)
Grade 4 10 (13.9) 9 (12.7)
Patellofemoral joint K/L grade, no. (%) 0.278
Grade 0 2 (2.8) 0 (0.0)
Grade 1 25 (34.7) 18 (25.4)
Grade 2 30 (41.7) 32 (45.1)
Grade 3 9 (12.5) 16 (22.5)
Grade 4 6 (8.3) 5 (7.0)
Location of patellofemoral osteoarthritis, no. (%) 0.522
Medial facet 4 (5.6) 2 (2.8)
Lateral facet 18 (25.0) 25 (35.2)
Mixed (medial and lateral) facet 23 (31.9) 26 (36.6)
Patellar alignment and trochlear morphology
Lateral displacement, % 8.64 ± 5.97 10.2 ± 5.54 0.077
Tilting angle, degreesb 5.43 ± 4.15 6.47 ± 4.59 0.114
Sulcus angle, degrees 133.9 ± 6.61 132.7 ± 5.25 0.237
JKOM
Pain and stiffness (0–32 points) 8.82 ± 6.05 9.48 ± 5.69 0.444
Activities of daily living (0–40 points) 7.97 ± 7.40 8.45 ± 6.61 0.394
Participation in social activities (0–20 points) 4.06 ± 4.21 3.63 ± 3.85 0.548
General health conditions (0–8 points) 2.99 ± 1.65 2.96 ± 1.39 0.821
Total score (0–100 points) 23.8 ± 16.3 24.5 ± 14.6 0.586
VAS score for knee pain, mm 3.56 ± 2.90 3.71 ± 2.74 0.617
K/L grade Kellgren/Lawrence grade, JKOM Japanese Knee Osteoarthritis Measure, VAS Visual analog scale
**Based on unadjusted analysis (Student’s t-test [age, weight, and sulcus angle], Mann-Whitney U test [height, body mass index, lateral displacement, tilting angle,
JKOM score, and VAS score for knee pain], or chi-square/Fisher's exact tests [sex, tibiofemoral and patellofemoral joint K/L grades, and location of patellofemoral
osteoarthritis]) of the completer and non-completer groups
aExcept where otherwise indicated, values are mean ± SD
bA positive value for tilting angle indicates patellar tilt toward the lateral side and a negative value to the medial side
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Recently, Nicholls et al. characterized distinct trajectories
of knee pain using latent class growth curve modeling ana-
lysis, showing that patients labeled “mild, non-progressive,”
“moderate,” or “severe, non-improving” constituted stable
subgroups of two independent large datasets [5]. Other
studies also demonstrated that trajectories of pain severity
and self-reported functional disability in patients with knee
OA are often non-progressive over several years [20, 36].
Although we did not directly identify distinct subgroups
using statistical methods such as latent class growth mode-
ling [5] and latent class cluster analysis [21], patients with
coexisting PFOA and TFOA in the present study likely
correspond to the “severe, non-improving” class with
consistently severe symptoms (Table 3). The presence of
persistently bad but not worsening pain and functional dis-
ability throughout the year was unexpected. Our results
may indicate that clinical symptoms and functional dis-
ability in patients with mixed TF and PF joints disease
are not necessarily progressive despite the more fre-
quent presence of risk factors of progression of clinical
OA, such as quadriceps weakness [13, 14] and altered
gait biomechanics [14]. Nevertheless, the longer dur-
ation of worse clinical symptoms and pain-related func-
tional disability in patients with coexisting PFOA could
lead to a further functional decline, limited participa-
tion in social activities, and decreased quality of life. A
long-term prospective study with a large sample size,
following the trajectory of the clinical symptoms and
functional disability in patients with coexisting PFOA
and TFOA, would be of particular interest in answering
this question.
Previous longitudinal studies of clinical symptom pro-
gression suggested heterogeneous outcomes in patients
with knee OA, with knee pain improving in only some
patients [2–5]. In the present study, heterogeneous out-
comes in terms of knee pain were confirmed in patients
Table 2 Comparison of characteristics between patients with coexisting PFOA and those with isolated TFOAa
Variables TFOA + PFOA (n = 45) Isolated TFOA (n = 27) P-value**
Age, years 75.2 ± 8.86 71.6 ± 6.21 0.064
Women, no. (%) 33 (73.3) 20 (74.0) 0.945
Height, meters 1.54 ± 0.08 1.57 ± 0.08 0.120
Weight, kg 59.6 ± 10.2 55.7 ± 10.2 0.125
Body mass index, kg/m2 25.1 ± 3.76 21.7 ± 5.29 0.002
Tibiofemoral joint K/L grade, no. (%) 0.001
Grade 2 23 (51.1) 25 (92.6)
Grade 3 13 (28.9) 1 (3.7)
Grade 4 9 (20.0) 1 (3.7)
Patellofemoral joint K/L grade, no. (%) –
Grade 0 0 (0) 2 (7.4)
Grade 1 0 (0) 25 (92.6)
Grade 2 30 (66.7) 0 (0)
Grade 3 9 (20.0) 0 (0)
Grade 4 6 (13.3) 0 (0)
Location of patellofemoral osteoarthritis, no. (%) –
Medial facet 4 (8.9) –
Lateral facet 18 (40.0) –
Mixed (medial and lateral) facet 23 (51.1) –
Patellar alignment and trochlear morphology
Lateral displacement, % 10.4 ± 5.87 5.73 ± 5.01 <0.001
Tilting angle, degreesb 4.52 ± 4.27 6.95 ± 3.54 0.009
Sulcus angle, degrees 133.6 ± 6.49 134.4 ± 6.89 0.602
TFOA Tibiofemoral osteoarthritis, PFOA Patellofemoral osteoarthritis, K/L grade Kellgren/Lawrence grade
P-values indicating statistically significant differences (<0.05) are displayed in bold
**Based on unadjusted analysis (Student’s t-test [age, weight, and sulcus angle], Mann-Whitney U test [height, body mass index, lateral displacement, and tilting
angle], or chi-square/Fisher's exact tests [sex, tibiofemoral and patellofemoral joint K/L grades, and location of patellofemoral osteoarthritis]) of the TFOA + PFOA
and isolated TFOA groups
aExcept where otherwise indicated, values are mean ± SD
bA positive value for tilting angle indicates patellar tilt toward the lateral side and a negative value to the medial side
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with coexisting PFOA: 10 (22.2%) and 18 (40.0%) of the
45 patients showed improvement and worsening on
categorized VAS, respectively. To test the possibility that
categorizing the patients according to location of PFOA
may identify distinct subgroups with different trajectories
of clinical outcomes at 1-year follow-up, we performed ex-
plorative subgroup analysis (Table 4 and Fig. 1) and found
that patients with mixed PFOA had consistently severe
clinical symptoms, which exceeded the unacceptable level
(VAS > 30 mm) [34, 35] in more than 65% of the patients
after 1 year, whereas knee pain in patients with isolated
lateral PFOA was likely to decrease during this period.
Stefanik et al. showed that, in the Multicenter OA study
and Framingham OA cohort, magnetic resonance imaging
(MRI)-detected full-thickness cartilage loss and bone mar-
row lesion of any size in mixed PF joints were more likely
to be associated with knee pain than the same findings in
isolated medial or lateral PF joints [37]. Given that
adjusting for TF joint K/L grade reduced the significant
difference in knee pain between patients with mixed
PFOA and isolated lateral PFOA (data not shown), TF
joint severity could also contribute to knee pain differences
between the groups. Nevertheless, our findings suggest that
the heterogeneity of clinical outcomes in patients with
coexisting PFOA should be recognized, and mixed PF joint
disease might indicate a subgroup with more severe clinical
symptoms that are likely to exceed the unacceptable level.
Interestingly, the improvement in clinical symptoms in
patients with isolated lateral PFOA may not be accom-
panied by significant functional improvement (Table 4).
This may be a consequence of avoidance of activities be-
cause of anticipated pain and low vitality [38]. Therefore,
pain reduction should not be considered equivalent to
functional improvement, particularly that of performance-
based physical function [39, 40].
Our study has several limitations to be noted. It is un-
known whether the clinical symptoms and functional
disability at the 1-year follow-up were affected by a bias
due to missing values during this period. Therefore, follow-
up losses need to be minimized to exactly characterize pain
and functional changes in patients with coexisting PFOA.
However, there were no significant differences between pa-
tients who completed the follow-up study and those who
did not in baseline characteristics, which might indicate
that data are missing at random. We confirmed that base-
line knee pain intensity, which is a previously reported
prognostic factor for worsening pain and disability [41], did
not differ between completer and non-completer. Another
important limitation is the small sample size, as the study
might not have sufficient statistical power to detect a po-
tential association between presence of PFOA and clinical
outcome changes, particularly in patients with isolated
medial PFOA. Nevertheless, the result from the explorative
subgroup analysis demonstrated a potential dependence of
pain trajectory on the location of PFOA in patients with
coexisting PFOA; it is important to verify this finding in a
larger study with a long-term follow-up. Our finding may
help to set the foundation for a prospective cohort
study with the aim of better understanding different
pain and functional trajectories in patients with knee
Table 3 Changes in the JKOM and VAS scores after 1 year of follow-up
Variables TFOA + PFOA (n = 45) Isolated TFOA (n = 27) Two-way ANCOVAa
Baseline 1-year
follow-up
Mean change Baseline 1-year
follow-up
Mean change Timeb Groupc Interaction




10.9 ± 6.14 11.3 ± 8.31 0.38 (-1.16, 1.92) 5.22 ± 3.72 4.85 ± 4.28 -0.37 (-1.72, 0.98) 0.996 <0.001 0.738
Activities of daily living
(0–40 points)
11.2 ± 8.93 12.1 ± 9.10 0.93 (-1.18, 3.04) 4.15 ± 3.73 5.19 ± 5.31 1.04 (-0.43, 2.51) 0.430 <0.001 0.965
Participation in social
activities (0–20 points)
5.33 ± 4.64 4.33 ± 4.24 -1.00 (-2.47, 0.47) 2.00 ± 2.12 2.62 ± 3.68 0.62 (-0.50, 1.73) 0.778 0.010 0.237
General health conditions
(0–8 points)
3.20 ± 1.84 3.33 ± 1.51 0.13 (-0.42, 0.68) 2.63 ± 1.21 2.48 ± 1.50 -0.15 (-0.58, 0.28) 0.978 0.100 0.601
Total score
(0–100 points)
30.0 ± 17.5 30.1 ± 20.0 0.12 (-4.24, 4.48) 13.8 ± 7.93 15.3 ± 11.7 1.48 (-2.07, 5.03) 0.769 <0.001 0.803
VAS score for knee
pain, mm
40.8 ± 27.2 43.1 ± 30.9 2.33 (-6.15, 10.8) 26.9 ± 30.2 20.0 ± 18.8 -6.89 (-18.3, 4.57) 0.633 0.003 0.334
TFOA Tibiofemoral osteoarthritis, PFOA Patellofemoral osteoarthritis, ANCOVA Analysis of covariance, 95% CI 95% confidence interval, JKOM Japanese Knee
Osteoarthritis Measure, VAS Visual analog scale
P-values indicating statistically significant differences (<0.05) are displayed in bold
aAdjusted P-values were calculated from the ANCOVA adjusted for age, sex, and body mass index
bBaseline vs. 1-year follow-up
cPFOA + TFOA vs. isolated TFOA
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OA. Furthermore, the lack of patient information about
pain medication and rehabilitation treatment may have
restricted our analysis. These treatment effects might
contribute to the dependence of pain trajectory on
location of PFOA. Finally, we did not evaluate the loca-
tion of knee pain within the knee joint, including the
PF joint, although Stefanik et al. showed that self-
reported location of the anterior knee pain is not highly
specific in PF lesions detected with MRI [42]. As also
mentioned in the recently published paper [12], altered
patellar alignment was not a predictor of knee pain in-
tensity in patients with coexisting PFOA and TFOA
(data not shown); this runs counter to a theory that
altered patellar alignment causes increase in PF joint
stress (e.g., a lateral tilt of the patella leads to increased
contact stress on the lateral facet) that contribute to PF
joint pain via nociceptive mechanisms. Thus, the fact that
patients with coexisting PFOA had worse clinical symp-
toms does not have specific implications for compartment-
specific intervention.
Conclusions
Clinical symptoms and functional disability in patients
with coexisting PFOA were overall stable rather than
worsening at the 1-year follow-up. This indicates that
patients with coexisting PFOA may be a clinically severe
disease subgroup. Additionally, subgroup analysis re-
vealed that patients with isolated lateral PFOA had mild/
moderate knee pain, and their VAS scores were likely to
improve, whereas those with mixed PFOA exhibited
stable to worsening moderate/severe knee pain. This
suggests that patients with coexisting PFOA might have
heterogeneous clinical outcomes, and presence of mixed
PFOA might be an indicator of severe clinical knee OA.
Additional file
Additional file 1: Table S1. Comparison of baseline characteristics
between patients with isolated lateral, isolated medial, and mixed medial
and lateral (n = 23) PFOA*. (DOCX 38 kb)
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